Study Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer Medicine - Wall Street Journal

Wall Street Journal

Study Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer Medicine Wall Street Journal CHICAGO—Researchers said a drug being developed by Mylan Pharmaceuticals Inc. proved comparable to Roche Holding AG's Herceptin in a clinical trial, a new milestone in the effort to bring cheaper versions of some of biotechnology's best-known cancer ... Biosimilar Matches Trastuzumab in Metastatic HER2-Positive Breast CancerCancer Network Mylan's Herceptin biosim matches Roche original in safety, efficacy studyFiercePharma Cheaper Breast Cancer Drug Does Well in Clinical TrialU.S. News & World Report Reuters -StreetInsider.com -Bloomberg -Finance Daily all 10 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEhuBAo5gWWo4xWyCIswtYzTl3ydA&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779126286493&ei=Tg1SV7DdL4KK3AGYj4LgDA&url=http://www.wsj.com/articles/study-finds-mylans-biosimilar-drug-comparable-to-roche-cancer-medicine-1464988965
via IFTTT